NeuroDerm Raises $45 M in NASDAQ IPO

Rehovot-based NeuroDerm, which has developed a transdermal drug delivery system for the treatment of Parkinson’s disease, raised $45 million by issuing 4.5 million shares at $10 per share, giving it a company value of $164 million, after money. The amount raised could rise to $50 million, if the underwriters take up their option to buy a further 675,000 shares in the next 30 days. According to the prospectus it had filed, NeuroDerm had sought to raise $58-72 million at a company value of $290 million. Jefferies and Cowen & Company acted as the joint bookrunners on the deal with Oppenheimer and Roth Capital acting as secondary underwriters. The company will trade under the NDRM ticker. NeuroDerm’s main shareholders include Omrix Biopharmaceuticals founder Robert Taub (28%) who serves as Chairman, Uwe Wascher (25.9%) a former GE senior executive and close friend of Taub and private investor Prof. Shmuel Cabilly (22.2%), while Capital Point Ltd. (TASE:CPTP) holds 16.6%.